Current page location

Immunotherapy Convergence Research Center

Immunotherapy Convergence Research Group
Developing original technology for customized converged cell treatment and commercialization by establishing cell therapy system that combines gene immune cell treatment, antibody convergence treatment, anticancer agent convergence treatment using stem cell to treat incurable cancer
    Click on the name
researchers and research statement
name research fields
Inpyo Choi
/ Director
  • NK cell function regulation and NK cell therapy
Semi Kim
/ Principal Researcher
  • Understanding of Cancer Progression Mechanisms
  • Development of Molecular-Targeted Cancer Therapy
Tae-Don Kim
/ Principal Researcher
  • Elucidation of roles of noncoding RNAs in immune cell differentiation and activation
  • Development of CAR-NK cell therapy
Suk Ran Yoon
/ Principal Researcher
  • Regulation of NK cell differentiation and Clinical research for NK cell therapy
Lee, Hee Gu
/ Principal Researcher
  • Functional studies of target molecules in cancer cell
Yee Sook Cho
/ Principal Researcher
  • Investigation of disease- and patient-specific PSCs for their applications in disease modeling and cell therapy
Sun Jin Lee
/ Senior Researcher
  • The regulatory and functional study on the autophagy and disease-related genes)
Su Ui Lee
/ Senior Researcher
  • Signal Transduction of inflammatory diseases
Jungwoon Lee
/ Senior Researcher
  • Molecular mechanisms of induced pluripotency
  • Pluripotent stem cell-based disease modeling
Haiyoung Jung
/ Senior Researcher
  • Hematopoietic stem cell aging and rejuvenation
Hee Jun Cho
/ Senior Researcher
  • Molecular biology, Cancer biology
Mi-Ok Lee
/ Senior Researcher
  • Disease modeling using patient specific induced pluripotent stem cells
  • Therapeutics development of genetic disease
Jiyoon Noh
/ Researcher
  • Molecular biology of hematopoiesis, Development of stem cell derived therapy, Mechanism of cytotoxicity
Kwan Soo Hong
/ Principal Researcher
  • To investigate in vivo homing behavior of transplanted NK cells and anti-tumor efficacy for NK cell therapy, by using in vivo imaging technologies
Chang Hoon Lee
/ Senior Researcher
  • Development of Cancer immunotherapy drug
research areas
  • Development of HSC based gene NK cell therapy (PL1,2)
    • Clinical research on converged NK cell therapy
    • Development of CAR-NK cell therapy
    • Verification of effects of single cel imaging based immune cell
    • Development of 3 dimensional culture technology of immune cell based on injection type nano hydrogel compound<
  • Development of customized NK cell therapy using anticancer agent (PL3)
    • Development of anticancer agent that increases the sensitivity of cancer cell to NK cell attack
    • Development of anticancer agent with improved function based on stem cell origin NK cell
    • Development of technology that optimizes the mix therapy with NK cell therapy through liver cancer customized preclinical test
  • Assessment of anti-tumor efficacy for NK cell therapy by using in vivo imaging technologies
    • Investigation of in vivo homing behavior of transplanted NK cells for tumor therapy
    • Assessing anti-tumor efficacy using in vivo MR/NIR imaging technologies for NK, NK-chemical, and NK-antibody therapies)
  • Expected products/service
    • Providing cell therapy and treatment technology to treat incurable cancer which gives hope to patients with incurable cancers
    • Securing cell therapy library using stem cell
  • Beneficiary
    • Demand for technology - domestic large hospital, pharmaceutical companies, domestic bio venture companies, overseas pharmaceutical companies
    • Final beneficiary
      • Incurable cancer patients, who have no treatment or therapy as of now
      • Cancer patients who have not responded to existing therapy
      • Cancer patients who experience recurrence of cancer even though they received existing therapy